Merck & Company Inc (MRK)vsSyndax Pharmaceuticals Inc (SNDX)
MRK
Merck & Company Inc
$148.78
+0.54%
HEALTHCARE · Cap: $365.34B
SNDX
Syndax Pharmaceuticals Inc
$18.20
+1.28%
HEALTHCARE · Cap: $1.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 26290% more annual revenue ($66.57B vs $252.25M). MRK leads profitability with a 4.8% profit margin vs -87.5%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
SNDX
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.2%
Fair Value
$83.04
Current Price
$148.78
$65.74 premium
Intrinsic value data unavailable for SNDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 91.8% year-over-year
Areas to Watch
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 107.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SNDX
The strongest argument for SNDX centers on Revenue Growth. Revenue growth of 91.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SNDX
The primary concerns for SNDX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 39.03 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while SNDX is a hypergrowth play — different risk/reward profiles.
SNDX carries more volatility with a beta of 0.37 — expect wider price swings.
SNDX is growing revenue faster at 91.8% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Syndax Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?